Worse Outcome in Patients with Acute Stroke and Atrial Fibrillation Following Thrombolysis*

Michael Findler MD1, Jeremy Molad MD1, Natan M Bornstein MD1,2 and Eitan Auriel MD MSc3

1Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Department of Neurology, Carmel Medical Center, Haifa, Israel

ABSTRACT: Background: Atrial fibrillation (AF) is the most common arrhythmia and a common cause of ischemic stroke. Stroke patients with AF have shown to have a poorer neurological outcome than stroke patients without AF.

Objectives: To determine the impact of pre-existing AF on residual degree of disability in patients treated with IV thrombolysis.

Methods: In this case-control study, data of 214 stroke patients (63 with AF, 151 without AF) were collected from the National Acute Stroke Israeli Registry, a nationwide quadrennial stroke database. Stroke severity and outcome were compared using the National Institute of Health Stroke Scale (NIHSS) at admission and the modified Rankin Scale (mRS) at admission and discharge. Demographics and stroke characteristics were also compared between the groups.

Results: Stroke severity, as determined by the NIHSS at admission, was higher in the AF group than the non-AF. In the group of patients who were treated with intravenous tissue plasminogen activator (tPA), more patients had favorable outcomes (mRS = 0–1 at discharge) in the non-AF group than in the AF group (P = 0.058, odds ratio = 2.217, confidence interval 0.973 to 5.05).

Conclusions: Our study suggests a worse outcome for thrombolized patients with AF compared to non-AF stroke patients. Therefore, AF itself is a poor prognostic factor for tPA sensitivity regarding the chance of revascularization and recovery after intravenous tPA.

KEY WORDS: atrial fibrillation, thrombolysis, National Institute of Health Stroke Scale (NIHSS), tissue plasminogen activator (tPA)

To date, rapid and effective revascularization is the mainstay of acute ischemic stroke treatment. Tissue plasminogen activator (tPA) is the standard, and until recently the only treatment for acute stroke. It has been found to improve outcome in about 30% of all acute stroke patients. In the present study we sought to determine the impact of pre-existing AF on residual degree of disability in thrombolized patient.

PATIENTS AND METHODS

This retrospective case-control study enrolled post-tPA acute ischemic stroke patients from the National Acute Stroke Israeli Registry as described by Tanne and colleagues [6,7]. Data were based on the quadrennial 2 month period (February to March 2004, March to April 2007, April to May 2010, April to May 2013) of the National Acute Stroke Israeli Registry. The registry was approved by the ethical committees of all participating medical centers. Data were documented by each stroke unit in the participating centers. Patients were assessed both at admission and discharge. Data collected included demographic and clinical baseline characteristics as well as localization of the stroke. Stroke severity was determined by the National Institute of Health Stroke Scale (NIHSS) at admission, and the modified Rankin Scale (mRS) at both admission and discharge. Comparisons between patients with and without AF were conducted using the t-test, chi-square test and Kruskal-Wallis test for the median. Logistic regression was used to explore the association of mRS and AF accounting for the covariates of age, gender and admission mRS. Statistical analysis was performed using SAS statistical software version 9.4 (SAS Institute, USA).

RESULTS

The study population comprised 214 patients aged 18 years and older who were hospitalized in 27 hospitals in Israel with acute ischemic stroke and received thrombolytic treatment. Of them, 63 had AF (age 72.6 ± 12.4 years, 40% men), the remaining 151 stroke patients had no documented AF (age 66.2 ± 11.7 years, 65% men).

Baseline characteristics, vascular risk factors and comorbid conditions are listed in Table 1. AF patients were significantly older than non-AF patients. Hypertension, heart failure and...
renal failure were more prevalent among the AF group. The frequency of prior stroke and/or transient ischemic attack (TIA) did not differ between the groups. Patients with AF had significantly higher C-reactive protein (CRP) values on admission (mean 34.5 ± 53.9 vs. 7.4 ± 9.7, P < 0.001). As expected, more patients with AF were previously treated with anti-aggregation or anticoagulation medications. Only one patient received anticoagulation treatment in the non-AF group vs. 12 (19%) in the AF group.

**STROKE CHARACTERISTICS**

Patients with AF more commonly presented with decreased consciousness (30% vs. 16%, P < 0.05). Presentation with visual disturbances was more common in AF than non-AF patients (29% vs. 17%, P < 0.05). Involvement of anterior circulation was more common in AF patients whereas posterior circulation strokes were more common in non-AF patients [Table 2].

**NEUROLOGIC STATUS**

Stroke severity, determined by NIHSS scores at admission, was higher in the AF than for the non-AF group. More patients had favorable outcomes (mRS 0–1 on discharge) in the non-AF group. This remained almost significant when adjusted for possible explanatory variables (gender, age, severe NIHSS defined as > 6) (P = 0.058, odds ratio = 2.217, confidence interval 0.973 to 5.05) [Table 3].

**DISCUSSION**

In the current study we found that among acute ischemic stroke patients receiving thrombolytic treatment in Israel, AF was associated with almost significant less favorable outcome in a multivariable regression.

Previous studies, not focusing exclusively on post tPA patients, have shown that cardio-embolic stroke is associated with a greater degree of neurological deficit and poorer outcome [8]. Of interest, a recent study indicated that AF in stroke patients is associated with greater volume of more severe hypoperfusion resulting in increased infarct growth and worse stroke outcomes. The latter was attributed to poorer collateral circulation quality [5]. Another possible cause is the sudden vessel occlusion by an emboli, as opposed to a more gradual process of chronic hypoperfusion in patients with atherosclerosis in large vessels or cerebral small vessel disease. Patients with AF are also older, have more co-morbidities and are more prone to bleeding than non-AF patients [1-3].

In thrombolized patients, AF has been suggested to be a cause of tPA resistance. Other factors preceding poor outcome include the location, size and composition of the occluding
thrombus [14,15]. A possible connection between thrombus composition, AF and tPA resistance was shown in recent histologic studies of the retrieved thrombi. These studies have shown that arterial platelet-rich clots are, in particular, more resistant to thrombolysis mediated by tPA [16]. This result is supported by the concept that cardio-embolic thrombi, being formed in regions of stasis or slow flow in the atrium, are mainly composed of entrapped erythrocytes, while thrombi occurring in atherosclerotic large arteries are mainly composed of fibrin and platelets. Confirmation of that assumption was recently shown by a study that evaluated the composition of clots retrieved by mechanical thrombectomy [17]. The lower fibrin proportion in cardio-embolic clots might provide a possible explanation to the tPA resistance concept as tPA targets fibrin activity within the clot.

The main strength of our study is the large sample size obtained from data collected in the NASIS survey, which is a national, prospective, multicenter study. Another strength is that all patients were evaluated by stroke specialists on admission and at discharge. The main disadvantages are the retrospective data collection obtained from a prospective study and not having mRS scores at 3 months but only at discharge. We also acknowledge not having data regarding bleeding rate and international normalized ratio values in patients receiving warfarin (n=13).

CONCLUSION
Our study suggests worse outcomes in thrombolized patients with AF compared with their non-AF counterparts. These findings, however should not discourage thrombolytic treatment, which has been shown to be beneficial and safe in both AF and non-AF acute ischemic stroke patients. However, it might encourage the use of an endovascular thrombectomy approach, especially in light of recent studies showing clear and persistent advantage for this approach in selected patients [18].

References

Correspondence
Dr. E. Auriel
Dept. of Neurology, Carmel Medical Center 3436212, Haifa, Israel
Fax: (972-4) 825-0693
e-mail: eitannmans@gmail.com

Capsule
Fighting filoviruses with antibody therapy
Ravn and Marburg viruses cause hemorrhagic fever with high morbidity rates in humans. Mire and co-authors tested the ability of previously identified human monoclonal antibodies to protect guinea pigs from lethal infection. One candidate antibody was administered 5 days after otherwise lethal Marburg or Ravn infection in nonhuman primates and was able to reduce clinical symptoms and confer almost uniform protection. This antibody is a promising therapeutic that could be helpful in future filovirus outbreaks.

Sci Transl Med 2017; 9.; eaai8711
Eitan Israeli